{"id":131430,"date":"2023-02-22T11:57:03","date_gmt":"2023-02-22T11:57:03","guid":{"rendered":"https:\/\/fin2me.com\/?p=131430"},"modified":"2023-02-22T11:57:03","modified_gmt":"2023-02-22T11:57:03","slug":"these-23-biotech-stocks-generated-triple-digit-returns-in-just-6-months","status":"publish","type":"post","link":"https:\/\/fin2me.com\/business\/these-23-biotech-stocks-generated-triple-digit-returns-in-just-6-months\/","title":{"rendered":"These 23 Biotech Stocks Generated Triple-Digit Returns In Just 6 Months"},"content":{"rendered":"
The following stocks that were featured on our site between July and December 2022 delivered triple-digit gains. Were these stocks part of your portfolio? <\/p>\n
\n Headlines<\/p>\n Published Date<\/p>\n Published Price<\/p>\n Maximum Price Since Publishing<\/p>\n Last Closing Price<\/p>\n Max Gain %<\/p>\n VIGL – Vigil Neuroscience’s IPO Lock-up Period Ends Tomorrow <\/p>\n Jul.5<\/p>\n $2.36<\/p>\n $16.77<\/p>\n $11.28<\/p>\n 610%<\/p>\n CINC- CinCor Pharma’s IPO Lock-up Period Ends On July 6<\/p>\n Jul.5<\/p>\n $19.7<\/p>\n $43.15<\/p>\n $29.15<\/p>\n 119%<\/p>\n GLSI – Greenwich LifeSciences Rallies On Removal Of Clinical Hold<\/p>\n Jul.12<\/p>\n $9.84<\/p>\n $21.50<\/p>\n $15.10<\/p>\n 118%<\/p>\n FREQ – Will Frequency Hit The Right Notes? <\/p>\n Jul.15<\/p>\n $2.55<\/p>\n $5.59<\/p>\n $0.68<\/p>\n 119%<\/p>\n VRNA – Will Verona’s COPD Trial Data ENHANCE Its Stock Price?<\/p>\n Jul.19<\/p>\n $5.98<\/p>\n $26.44<\/p>\n $20.54<\/p>\n 342%<\/p>\n VKTX – Viking Therapeutics To Resume Phase Ib Trial Of VK0214 <\/p>\n Jul.19<\/p>\n $3.45<\/p>\n $11.80<\/p>\n $11.03<\/p>\n 242%<\/p>\n NUVL – Will Nuvalent’s ARROS-1 Hit The Target?<\/p>\n Aug.10<\/p>\n $17.00<\/p>\n $40.43<\/p>\n $31.36<\/p>\n 137%<\/p>\n VTYX – Ventyx Biosciences Awaits VTX958 Trial Data <\/p>\n Aug.11<\/p>\n $17.19<\/p>\n $44.98<\/p>\n $42.50<\/p>\n 161%<\/p>\n WVE – What’s Causing Wave To Rise?<\/p>\n Aug.12<\/p>\n $3.14<\/p>\n $7.12<\/p>\n $4.32<\/p>\n 127%<\/p>\n AKRO – Akero – Of NASH And HARMONY…<\/p>\n Aug.22<\/p>\n $11.86<\/p>\n $54.88<\/p>\n $44.10<\/p>\n 362%<\/p>\n SPRB – Spruce Biosciences – Eyeing PCOS, CAH Treatment Markets<\/p>\n Sep.15<\/p>\n $1.74<\/p>\n $3.57<\/p>\n $2.40<\/p>\n 105%<\/p>\n AKUS – Did You Hear This? <\/p>\n Sep.15<\/p>\n $4.50<\/p>\n $15.50<\/p>\n NA<\/p>\n 244%<\/p>\n ANTX – AN2 Therapeutics’ IPO Lock-up Period Ends On Sep. 21<\/p>\n Sep.20<\/p>\n $9.58<\/p>\n $21.04<\/p>\n $13.32<\/p>\n 119%<\/p>\n MHUA – Meihua International – Getting Back On Track?<\/p>\n Sep.20<\/p>\n $5.52<\/p>\n $39.00<\/p>\n $39.00<\/p>\n 606%<\/p>\n HROW – Will Harrow’s AMP-100 Score FDA Nod?<\/p>\n Sep.21<\/p>\n $8.35<\/p>\n $20.31<\/p>\n $16.96<\/p>\n 143%<\/p>\n MDGL – Madrigal – Gearing Up For MAESTRO-NASH Data<\/p>\n Sep.26<\/p>\n $64.99<\/p>\n $315.45<\/p>\n $288.76<\/p>\n 385%<\/p>\n IMVT – Immunovant’s Batoclimab – A Pipeline In Itself? <\/p>\n Oct.5<\/p>\n $7.84<\/p>\n $20.24<\/p>\n $18.16<\/p>\n 158%<\/p>\n ALBO – Can Albireo’s Bylvay ASSERT Efficacy In Alagille Syndrome?<\/p>\n Oct.6<\/p>\n $20.00<\/p>\n $45.23<\/p>\n $43.76<\/p>\n 126%<\/p>\n ARDX – Will Ardelyx’ Xphozah Make It To The Finish Line?<\/p>\n Oct.13<\/p>\n $1.34<\/p>\n $3.43<\/p>\n $2.94<\/p>\n 155%<\/p>\n MLTX – MoonLake – Developing Next-level Therapies To Elevate Care<\/p>\n Oct.19<\/p>\n $8.28<\/p>\n $18.71<\/p>\n $18.18<\/p>\n 125%<\/p>\n BIVI – Will Christmas Come Early For BioVie?<\/p>\n Nov.9<\/p>\n $4.56<\/p>\n $14.38<\/p>\n $5.64<\/p>\n 215%<\/p>\n NAMS – NewAmsterdam Pharma Exploring High Risk Cardiovascular Disease Landscape<\/p>\n Nov.30<\/p>\n $9.00<\/p>\n $18.70<\/p>\n $13.45<\/p>\n 107%<\/p>\n RIGL – Rigel Soars As FDA Approves Acute Myeloid Leukemia Drug<\/p>\n Dec.2<\/p>\n $0.94<\/p>\n $2.04<\/p>\n $1.59<\/p>\n 117%<\/p>\n *The “Last Closing Price” refers to the closing price recorded on February 21, 2023. <\/p>\n |